. In patients with central nervous system disease, oversecretion of acid has been implicated as the primary cause of gastric mucosal injury (11) . In addition, adult patients with head trauma, major trauma, sepsis, and respiratory failure required larger doses of continuous infusion ranitidine as compared with patients without these risk factors (12) , suggesting these patients may also produce larger amounts of gastric acid. Similar results have been reported in pediatric patients (6) . Children with high Pediatric Risk of Mortality (PRISM) scores characterizing severe illness had low gastric pH (6) . In addition, Gedeit (6) demonstrated that pediatric patients with central nervous system illnesses spent more time with a gastric pH Ͻ4.0 and demonstrated worse control of gastric pH when compared with all other patients. Thus, to achieve gastric pH control, certain subpopulations of critically ill children may require larger doses of acidsuppressant therapy.
Omeprazole represents a class of agents that reduces gastric acid secretion by inhibiting the hydrogen-potassium adenosine-triphosphatase pump of the parietal cell (13, 14) . Until recently, the use of these proton pump inhibitors had been limited in critical care populations by the lack of an intravenous or liquid dosage preparation (13, 15, 16) . However, Phillips et al. (15) described the safe and efficacious use of a simplified omeprazole suspension for prophylaxis of stressrelated mucosal damage in critically ill, ventilated adults. Limited information is available describing the efficacy of omeprazole suspension in critically ill children (17, 18) . The objectives of this study were to evaluate the efficacy of omeprazole suspension in increasing gastric pH to Ն4 for at least 75% of the dosing interval in children in a pediatric intensive care unit and to determine the optimal dosing regimen of omeprazole suspension to achieve this goal.
MATERIALS AND METHODS

Study Design.
This was an open-label descriptive pharmacodynamic study conducted in a 26-bed tertiary-care pediatric intensive care unit. This study was approved by the University of Utah Institutional Review Board.
Study Subjects. Children between the ages of 1 and 18 yrs with respiratory failure requiring mechanical ventilation and an additional risk factor for stress ulcer formation were eligible for enrollment. The additional risk factors included: PRISM III score Ն10 (19), multisystem organ failure (failure of Ն3 organ systems), prolonged hypoperfusion (shock requiring inotropic support for maintenance of cardiac output or blood pressure), coagulopathy (international normalized ratio Ն1.5 in the absence of anticoagulants), multiple trauma, intracranial disease or head trauma, thermal injury (Ն15% body surface area), organ transplant recipient, and high-dose glucocorticoid administration. Patients with the following conditions were excluded from enrollment: patients receiving gastric feedings, known gastrointestinal hemorrhage, therapy with agents that have a narrow therapeutic index and are known to interact with omeprazole (e.g., cyclosporine, carbamazepine, methotrexate), known coagulation defects, potential for swallowed blood (e.g., facial fractures, oral lacerations), status post-gastric surgery, history of vagotomy, basilar skull fracture, and high gastric output (Ͼ20 mL/kg/day). The study was discontinued in patients who received gastric feedings after enrollment. Subjects were followed until the initiation of gastric feeds, extubation, or death.
Informed consent was obtained from the child's parent(s). Obtaining assent from children Ͼ7 yrs old was not feasible because eligible patients were critically ill, mechanically ventilated, and sedated.
Procedures. After enrollment, a nasogastric pH probe (GrapHprobe or Accusite Feeding Tubel Zinetics, Salt Lake City, UT) was placed in each patient and gastric pH was continuously monitored. Any previous orders for acid-suppressant therapy were discontinued. Omeprazole suspension was prepared according to published instructions by Phillips et al. (15) . The study was initiated when the subject's gastric pH was Ͻ4.0. A single 1-mg/kg dose (maximum, 20 mg) of omeprazole suspension was administered through a nasogastric tube. The nasogastric tube was flushed with 5-10 mL of water and clamped for a minimum of 30 mins. This initial omeprazole dose was based on current dosing recommendations for other pediatric indications (20) .
Subsequent doses of omeprazole and the dosing interval were then titrated based on gastric pH according to predetermined criteria outlined in Figures 1 and 2 . If the gastric pH remained Ͻ4.0 for Ͼ6 hrs after three dosage increases, the patient's participation in the study was terminated and the patient was treated according to the discretion of the attending physician. During all phases of the dose titration, if the subject's gastric pH fell below 4 for a minimum of 2 consecutive hrs in the first half of the dosage interval, intermittent doses of antacid were administered to raise gastric pH and provide gastric mucosal protection. Increases in gastric pH that were temporally related to antacid administration were disregarded in determining whether to uptitrate the omeprazole dose ( Figs. 1 and 2) .
Data Collection. Each patient's gastric pH was monitored continuously throughout the study and was charted hourly. Additional data collection included patient demographics, admission diagnoses, pertinent medical history, concomitant medications, data required for calculation of PRISM III scores (19) , length of pediatric intensive care unit (PICU) admission, and evidence of gastrointestinal bleeding.
Data Analysis. Subjects were stratified post hoc into three groups based on their pharmacologic response to omeprazole suspension. A rapid response was defined by achievement of gastric pH Ͼ4 sustained for a minimum of 12 hrs within 24 hrs after beginning therapy. A late response was defined as no sustained increase in gastric pH (Ͼ4) in the first 24 hrs followed by a sustained gastric pH Ͼ4 after the omeprazole dose was increased. Patients were classified as nonresponders if gastric pH was not sustained above 4 despite dosage increases.
Data were analyzed using appropriate descriptive and inferential statistics. For parametric data, analysis of variance (ANOVA) and the Bonferonni post hoc test were used to compare multiple groups. For nonparametric data, Kruskal-Wallis analysis of variance on Ranks and Dunn's all pairwise comparisons (post hoc) were performed. (Sigmastat 2.03l SPSS, Chicago, IL). Data are reported as mean Ϯ SD. Statistical significance was achieved at p Ͻ .05.
RESULTS
Twenty-two subjects (13 males, nine females) ranging in age from 13 mos to 
the data analysis. Two patients met exit criteria by beginning gastric feeds before the initiation of omeprazole and two patients had gastric pH Ͼ4 for the entire duration of monitoring, and the study was therefore not initiated. The mean duration of study participation was 4.7 Ϯ 3.8 days and ranged from 1 to 18 days.
Each of the study subjects was intubated and mechanically ventilated, and each had at least one additional risk factor for the development of stress ulceration. Second risk factors included septic shock (n ϭ 3), traumatic brain injury (n ϭ 6), multiple trauma, including traumatic brain injury (n ϭ 3), nontraumatic brain injury, i.e., stroke (n ϭ 4), and hemolytic uremic syndrome with associated high severity of injury score (n ϭ 2). The mean PRISM III (19) score was 8.2 Ϯ 6.2 and was Ͼ10 in seven of the 18 patients. Before study enrollment, all subjects receiving stress ulcer prophylaxis (n ϭ 16) were treated with ranitidine.
Overall, 50% of patients were rapid responders to omeprazole suspension, 28% were late responders, and 22% were nonresponders. Demographics for the three groups of patients are reported in Table 1 . The initial omeprazole dose for all patients ranged from 0.22 to 1.0 mg/ kg. Rapid responders (n ϭ 9) demonstrated a sustained gastric pH Ͼ4 after the initial dose of omeprazole suspension (Fig. 3) . Late responders (n ϭ 5) did not have improved gastric pH after the initial dose, but eventually responded after the dosage and/or frequency of omeprazole administration was increased (Fig. 4 ). There were four nonresponders who did not have an effective increase in gastric pH despite increases in drug dosage and dose frequency (Fig. 5) .
There was no clinically or statistically significant difference in the initial milligram per kilogram dose between the different groups (rapid responder, late responder, and nonresponder) ( Table 1) . The subject who received the smallest dose (0.22 mg/kg) was a rapid responder. There was no correlation between the risk factors for stress ulcer formation and the patient's response to omeprazole.
After the initial dose of omeprazole, the median time that gastric pH remained Ͼ4 in all patients was 4 hrs and the duration of action ranged from 0 (n ϭ 3) to 68 hrs. Each of the three patients with no initial response responded well to the repeat dose administered at 12 hrs; therefore, these patients were considered rapid responders. Among the groups of responders, there was a statistically significant difference in the duration of action (p ϭ .05, ANOVA on Ranks). The rapid responder group (n ϭ 6) had a median duration of action of 38.5 hrs. This interval was significantly longer than that of the nonresponders (n ϭ 4), who had a median duration of action of 2 hrs (p Ͻ .05).
Only four subjects were maintained on the originally prescribed dose. One subject required a decrease in the total daily dose. Two of the rapid responders (one died, one extubated) and one of the nonresponders (extubated) did not receive subsequent doses. The remaining ten subjects required an increase in omeprazole dosage, frequency, or both. After a dose was determined to be inadequate, these ten subjects received supplemental doses of antacid until administration of the next scheduled dose of omeprazole. The average final daily dose of omeprazole suspension required by the early responders was 0.72 Ϯ 0.27 mg/kg/day. In the late responder and nonresponder groups, the average final daily doses were 1.58 Ϯ 0.80 mg/kg/day and 1.1 Ϯ 0.33 mg/kg/day, respectively. The late responders received a significantly higher final daily dose of omeprazole than the early responders (p ϭ .04; ANOVA). There were individuals in each of the groups who required twice-daily dosing.
Rapid responders reached the goal pH of Ն4 and Ͻ7 for 78 Ϯ 25% of the first 12 hrs after omeprazole dosing. This is in contrast to the late and nonresponders who were within the goal range only 43 Ϯ 19% and 20 Ϯ 25% of that time period, respectively (p ϭ .004). After titration of the maintenance dose, rapid responders maintained a gastric pH between 4.0 and 7.0 for 74 Ϯ 18% of the dosing interval. The late and nonresponders achieved the goal pH for 66 Ϯ 22% and 35 Ϯ 32% of the dosing interval, respectively (Fig. 6 ) (p ϭ .72).
One rapid responder had an episode of upper gastrointestinal bleeding requiring transfusion of fresh-frozen plasma. Endoscopy revealed esophageal trauma and bleeding and mild gastritis with no gastric or duodenal bleeding. He was withdrawn from the study and was maintained on omeprazole and sucralfate.
DISCUSSION
In this study, we found that 50% of the children studied did not achieve an adequate rise in gastric pH for stress ulcer prophylaxis after a 1-mg/kg dose (maximum, 20 mg) of omeprazole suspension. Stress ulceration is a rare but serious complication of critical illness in children. The reported incidence of gastrointestinal bleeding in critically ill children is 6.4% to 10.2% with 1.5% to 1.6% of patients having clinically significant bleeding (4, 5, 21) . The complications of clinically significant bleeds may be substantial. It has been reported that an episode of clinically significant bleeding from stress ulceration increases the PICU length of stay by 15 days, increases the duration of intubation by 6 days, and increases the need for blood product by five units (21) . Associated costs have been estimated at $14,000 (1999 Canadian dollars) per episode of clinically significant gastrointestinal bleeding (21) .
Omeprazole suspension has been shown to prevent clinically significant upper gastrointestinal bleeding in critically ill adults and effectively maintain excellent control of gastric pH without producing toxicity (15 ,22) . Given the relatively uncommon occurrence of clinically significant bleeding from stress ulceration in critically ill children, this study was not powered to demonstrate a decreased incidence of bleeding. Rather, we chose to investigate whether the administration of omeprazole suspension could maintain the gastric pH of critically ill children at a level previously demonstrated to protect against the development of stress ulceration (6 -9) . If omeprazole suspension could be shown to reliably increase the gastric pH to Ͼ4, it follows that this preparation should be a viable option for stress ulcer prophylaxis in children.
However, the results of this study do not demonstrate a reliable and sustained increase in gastric pH in critically ill children after administration of omeprazole suspension. Fifty percent of the patients in our study were either late responders or nonresponders. These subjects were not adequately protected from stress ulceration with our standard dosing of omeprazole suspension (1 mg/kg to a maximum dose of 20 mg). This rate of treatment failure is greater than that previously observed with continuous intravenous ranitidine (10) . Approximately one-fourth of the patients in this study were late responders and did not have a sustained gastric pH Ͼ4 until 57.7 Ϯ 37.6 hrs after initiating therapy. In addition, late responders required a significantly higher dose of omeprazole suspension than rapid responders (1.58 mg/kg/ day vs. 0.72 mg/kg/day, respectively). Another one fourth of the patients were nonresponders who never achieved a sustained gastric pH Ͼ4 despite an average dose of 1.1 mg/kg/day. The weights of the subjects in the nonresponder group were greater than in the other two groups; therefore, each subject in the nonresponder group started at the maximum initial dose of 20 mg, which resulted in a statistically insignificant lower milligram per kilogram initial dose than the other groups. Despite the dosage increases in nonresponding subjects, the daily milligram per kilogram maintenance dose remained lower than that of the late responders. It is conceivable that if dose titration had continued in the nonresponders that some subjects may have ultimately achieved adequate gastric acid suppression. However, without the intensive gastric pH monitoring used in this research study, the need for higher doses would not have been clinically apparent. Moreover, additional dose titration may have caused an unacceptable delay in reaching a therapeutic gastric pH Ͼ4.
In our PICU, gastric pH is monitored twice daily as the standard of care. Based on the continuous monitoring of gastric pH in this study, we found that all patients had periods of time when their gastric pH was in the goal range of 4 to 7. Our data suggest that the subjects who were either late responders or nonresponders may not have been identified with our standard monitoring, depending on when during the day gastric pH was measured.
The failure of 1-mg/kg/day dosing of omeprazole suspension in 50% of our patients was unexpected. Bergman (17) and Olsen (18) reported favorable results, including gastric pH and omeprazole serum concentrations, with this dosage regimen in pediatric liver and/or intestinal transplant patients. Although organ transplantation was an inclusion criterion for this study, no transplant recipients were enrolled. Our results may reflect the difference inpatient population and risk factors for stress ulceration. However, the data from the responders in our study support Olsen's recommendation for twice-daily dosing in pediatric patients (18) .
Previously published studies in critically ill adults have demonstrated that absorption of omeprazole suspension is similar after nasogastric, duodenal, or jejunal routes of administration (23) . This finding is important because omeprazole is acid labile and its administration into the stomach through a nasogastric tube may theoretically result in drug degradation and reduced bioavailability. Other pharmacokinetic studies in adults indicated that the relative bioavailability of omeprazole after single and multiple dose administration of the simplified omeprazole suspension was 81% and 58%, respectively, as compared with the capsule (24) . The lower bioavailablity of omeprazole suggests that the bicarbonate solution in which omeprazole suspension is prepared may be insufficient to completely protect the drug molecule from degradation in the acidic environment in the stomach. Our results are consistent with this theory in that almost all patients had an immediate increase in gastric pH. However, the increased gastric pH was not sustained in the late responder and nonresponder groups. It is possible that the neutralizing capacity of the bicarbonate vehicle was overcome by the high gastric acidity in these subjects and that the omeprazole was consequently degraded. However, because serum levels and the pharmacokinetics of omeprazole were not determined in this study, reduced bioavailability cannot be proven to be the cause of variable efficacy.
The pharmacokinetics of 10 or 20 mg of omeprazole administered as a single oral dose to children ages 2 to 16 yrs are comparable to values reported for adults (25) . In adults, it has been proposed that high initial loading doses of a proton pump inhibitor render the majority of the hydrogen-potassium adenosine-triphosphatase pumps ineffective, thus permitting a lower maintenance dose to be used to maintain inactivation of newly activated or regenerating pumps (26, 27) . Our data do not support this proposal in pediatric patients. The children enrolled in this study required a higher dose per kilogram than is suggested for adults (0.72-1.58 mg/kg/day vs. a standard adult dose of 20 -40 mg) and only one subject required a decrease in dosage during our titration.
This study was limited by two primary factors. First, we did not evaluate the pharmacokinetics of omeprazole. These data may have been valuable in determining whether the systemic absorption of omeprazole was lower in the late responder and nonresponder groups. Second, two children in the nonresponder group were extubated within days of enrollment. This limited the number of possible dosage increases and perhaps prevented us from determining the most efficacious dose. Yet, it is clinically apparent from our data that a large percentage of children who received omeprazole suspension and whose dose was titrated from an initial daily dose of 1 mg/kg (maximum, 20 mg) did not achieve adequate and expedient gastric acid suppression for stress ulcer prophylaxis.
We conclude from this study that omeprazole suspension has variable efficacy as an agent for stress ulcer prophylaxis in critically ill children. Although there are some children for whom this drug is useful, half of our subjects did not obtain adequate gastric acid suppression at the tested dose and these patients may not have been easily identified with standard gastric pH monitoring. If omepra- zole suspension is used for this indication, we suggest frequent monitoring of gastric pH for the initial 24 hrs of therapy to ensure an appropriate clinical response. Further studies are needed to determine whether administration of omeprazole in the stomach of critically ill children results in reduced bioavailability as compared with administration in the jejunum and whether higher doses are needed in some children to illicit the desired response.
